Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
anaplastic thyroid carcinoma
immunohistochemistry
neovasculature
poorly differentiated thyroid carcinoma
prostate-specific membrane antigen
theranostic
treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Nov 2021
14 Nov 2021
Historique:
received:
15
10
2021
revised:
01
11
2021
accepted:
10
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Several studies have demonstrated an expression of the prostate-specific membrane antigen (PSMA) in the cancer-related neovasculature of thyroid malignancies. Due to the poor prognosis and limited therapeutic options for patients with anaplastic (ATC) and poorly differentiated (PDTC) thyroid carcinoma, the aim of our study was to investigate the theranostic approach of PSMA expression in these patients. The PSMA uptake on Gallium-68 (
Identifiants
pubmed: 34830843
pii: cancers13225688
doi: 10.3390/cancers13225688
pmc: PMC8616254
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg Oncol. 2006 Apr;13(4):453-64
pubmed: 16474910
EJNMMI Res. 2020 Oct 22;10(1):128
pubmed: 33090273
Cancer Imaging. 2020 Mar 14;20(1):23
pubmed: 32169115
Clin Nucl Med. 2018 Aug;43(8):e265-e268
pubmed: 29894335
J Med Radiat Sci. 2017 Mar;64(1):52-60
pubmed: 28303694
Clin Nucl Med. 2017 Jan;42(1):20-25
pubmed: 27846003
Thyroid. 2002 Sep;12(9):747-54
pubmed: 12481939
Oncotarget. 2018 Jan 4;9(11):9867-9874
pubmed: 29515776
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97
pubmed: 20418080
Cancer J. 2015 Jul-Aug;21(4):267-73
pubmed: 26222078
Oncotarget. 2017 Jan 17;8(3):4268-4276
pubmed: 28002805
Thyroid. 2019 Mar;29(3):311-321
pubmed: 30747050
Pathol Res Pract. 2006;202(11):759-65
pubmed: 17029809
Clin Cancer Res. 2016 Jan 1;22(1):9-15
pubmed: 26728408
Cancer. 2005 Apr 1;103(7):1330-5
pubmed: 15739211
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2277-85
pubmed: 20694463
Nuklearmedizin. 2007;46(6):291-301
pubmed: 18084685
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613
pubmed: 28677048
Nucl Med Mol Imaging. 2017 Dec;51(4):360-361
pubmed: 29242733
Thyroid. 2008 Jul;18(7):713-9
pubmed: 18630999
EJNMMI Res. 2020 Mar 6;10(1):18
pubmed: 32144510
Thyroid. 2012 Nov;22(11):1104-39
pubmed: 23130564
Front Oncol. 2021 Mar 30;11:646387
pubmed: 33859946
J Nucl Med. 2016 Mar;57(3):367-71
pubmed: 26585062
J Cancer Res Clin Oncol. 2020 Feb;146(2):305-313
pubmed: 31897687
EJNMMI Res. 2019 Oct 15;9(1):93
pubmed: 31617002
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):667-668
pubmed: 29294167
Eur Arch Otorhinolaryngol. 2020 May;277(5):1507-1514
pubmed: 32060602
Urologe A. 2020 May;59(5):617-625
pubmed: 32377764
Hypoxia (Auckl). 2017 Apr 11;5:21-32
pubmed: 28443291
Thyroid. 2016 Nov;26(11):1588-1597
pubmed: 27480016
Mod Pathol. 2010 Sep;23(9):1269-78
pubmed: 20562850
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1971-5
pubmed: 26373947
Urology. 2017 Mar;101:e5-e6
pubmed: 28063603
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Eur Urol. 2017 Jan;71(1):145-146
pubmed: 27363386
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):170-1
pubmed: 25293865
Clin Nucl Med. 2007 Feb;32(2):145-9
pubmed: 17242574
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
World J Surg. 2007 May;31(5):934-45
pubmed: 17431717
Pathology. 2016 Oct;48(6):613-6
pubmed: 27567227
Cancer Control. 2005 Oct;12(4):254-60
pubmed: 16258498
Int J Cancer. 2012 Feb 1;130(3):694-704
pubmed: 21400508
Am J Transl Res. 2019 Sep 15;11(9):5888-5896
pubmed: 31632557
Eur J Nucl Med Mol Imaging. 2018 May;45(5):860-877
pubmed: 29335762
Cell Commun Signal. 2020 Jun 3;18(1):83
pubmed: 32493394